Best of ASCO - 2014 Annual Meeting

 

Welcome

Gastrointestinal Stromal Tumors (GIST)

Sarcoma

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).

Arun S. Singh

11017

Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.

Patrick Schoffski

11006

ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).

Desmond Yip

11023

Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).

Michael C. Heinrich

11022

Clinical characterization of patients with SDHC epimutation in gastrointestinal stromal tumors.

Maran Ilanchezhian

11033

Correlation of imatinib plasma trough concentrations with adverse reaction in Chinese gastrointestinal stromal tumors patients.

Yanzhe Xia

11034

Creation and characterization of a novel human PDGFRA D842V-mutant GIST cell line.

Lillian Rose Klug

e22512

Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).

Silvia Gasperoni

11032

Neurofibromatosis 1 (NF1) and gastrointestinal stromal tumors (GISTs): Five-year experience from a regional center in United Kingdom.

Venkata Ramesh Bulusu

11035

Racial disparity in incidence and survival for gastrointestinal stromal tumors (GIST): An analysis of SEER database.

Mark Bilinyi Ulanja

11037

Relationship among ETV1 genetic polymorphisms, PFS, and microRNA in gastrointestinal stromal tumors.

Haibo Qiu

e22513

Sequenced circulating tumor (ct) DNA to detect the molecular landscape in advanced GIST.

Ciara Marie Kelly

11036

The effect of gastrectomy in regorafenib treated GIST patients on outcome and drug exposure.

Nielka P. Van Erp

e22511